Edition:
United Kingdom

People: Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

234.92USD
4:59pm BST
Change (% chg)

$-3.78 (-1.58%)
Prev Close
$238.70
Open
$239.36
Day's High
$239.52
Day's Low
$234.69
Volume
189,346
Avg. Vol
611,217
52-wk High
$358.35
52-wk Low
$215.81

Mulligan, Richard 

Dr. Richard C. Mulligan, Ph.D. is an Independent Director of Biogen Inc. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative from 1996 to 2013. He also currently serves as Executive Vice Chairman of the Board of Sana Biotechnology, a private biotechnology company. From March 2017 to October 2018 Dr. Mulligan served as a Portfolio Manager at Icahn Capital LP. Prior to that, Dr. Mulligan was a founding partner of Sarissa Capital Management LP, a registered investment advisor, from 2013 to 2016. Prior to Harvard, Dr. Mulligan was a Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981.

Basic Compensation

Total Annual Compensation, USD 138,500
Restricted Stock Award, USD 269,447
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 407,947

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stelios Papadopoulos

613,476

Michel Vounatsos

16,168,600

Jeffrey Capello

4,476,720

Ginger Gregory

--

Susan Alexander

6,353,780

Michael Ehlers

7,046,650
As Of  31 Dec 2018